The anti-tumor effects of EZH2 inhibition may be through downregulation of cell-cycle related genes in PRAD and other AR-low NEPC-transitioning models (27, 28), potentially collaborating with its impact on AR signaling. Here, AR is linked to prostate adenocarcinoma.